Search for: "Artzt v. Artzt" Results 1 - 20 of 39
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
9 Oct 2020, 4:47 am by Pamela C. Maloney
The patent owner did not establish that the Board erred in its finding that the challenged claims were obvious in light of the prior art (Siemens Mobility, Inc. v. [read post]
” The Federal Circuit also held that the defendants were entitled to sanctions in the form of appellate attorney fees and double costs, against both the complaining individual and his legal counsel (Pirri v. [read post]
29 Aug 2020, 9:49 pm by Nicole D. Prysby
” These declarations alleged only “possible future injury” and failed to establish a substantial risk of harm (Association for Accessible Medicines v. [read post]
2 Nov 2020, 2:00 am by Emma Irwin (Bristows)
Wyeth referred Meade J. to the Idenix v Gilead and KCI v Smith & Nephew cases when making its submissions on the principles of the law on CGK. [read post]
24 Feb 2021, 9:11 am by Miquel Montañá (Clifford Chance)
This logic was followed by the U.S. courts in Monsanto v. [read post]
1 Mar 2021, 5:34 am by Ben Millson (Bristows)
Turning to de minimis, Arnold LJ noted that it was common ground that his own statement of the law in Napp v Dr Reddy’s [2016] EWHC 1517 (Pat) was accurate, and analysed whether three “groups” of infringement were de minimis. [read post]
8 Apr 2021, 4:59 am by Roya Ghafele (OxFirst)
Cases such as Conversant vs ZTE/Huawei, Philips vs TCL, TQ Delta v ZyXel or Optis v Apple pertain equally to the licensing of standard essential patents. [read post]
27 Feb 2021, 12:37 am by Matthieu Dhenne (Ipsilon)
The Court then reaffirms that the criteria identified by the Court of Justice in Huawei v. [read post]
On 4 December 2020, the English Patents Court handed down its decision in Neurim Pharmaceuticals (1991) Limited & Flynn Pharma Limited v Generics UK Limited (t/a Mylan) & Mylan UK Healthcare Limited, the main action proceedings regarding Neurim’s patent for Circadin, EP 1 441 702 (“EP 702”). [read post]
1 Feb 2021, 12:38 am by Matthieu Dhenne (Ipsilon)
She is notably the author of a famous doctoral thesis on international patent litigation awarded by the Prix Pierre Véron and the Prix Cercle Montesquieu in 2007, published in 2006 (you can order it here), and has kindly accepted to offer us two brief lectures on issues relating to FRAND litigation in a global context: which Judge can fix a global rate (Part 1)? [read post]
More from our authors: Vissers Annotated European Patent Convention by Derk Visser, Laurence Lai, Peter de Lange, Kaisa Suominen€ 105 Handbook of Blockchain Law: A Guide to Understanding and Resolving the Legal Challenges of Blockchain Technology by Matthias Artzt, Thomas Richter€ 181 Legal… [read post]
17 Nov 2020, 9:16 pm by Rik Lambers (Brinkhof)
The decision of the PI Judge of the District Court of The Hague in the Novartis v. [read post]
  In considering this question, Marcus Smith J considered the case law regarding the stay of proceedings and, in particular, the Court of Appeals judgment in IPCom v HTC[2]. [read post]
29 Jan 2021, 7:20 am by Nicolas Round (Bristows)
  If that turns out to the case then Illumina Cambridge Limited v Latvia MGI Tech SIA and others is a substantial judgment to mark this departure. [read post]
8 Dec 2020, 4:07 pm by Kluwer Patent blogger
” 3) Copyright vs data protection: CJEU grappling with the right to information about infringers by Giulia Priora “On 9 July 2020, the Court of Justice of the European Union (CJEU) delivered its judgment in Case C-264/19 Constantin Film Verleih v YouTube and Google Inc. [read post]